Murine leukemia virus-derived retroviral vector has differential integration patterns in human cell lines used to produce recombinant factor VIII

Abstract

ObjectiveNowadays recombinant factor VIII is produced in murine cells including in Chinese hamster ovary (CHO) and baby hamster kidney cells (BHK). Previous studies, using the murine leukemia virus-derived retroviral vector pMFG-FVIII-P140K, modified two recombinant human cell lines, HepG2 and Hek293 to produce recombinant factor VIII. In order to characterize these cells, the present study aimed to analyze the integration pattern of retroviral vector pMFG-FVIII-P140K.MethodsThis study used ligation-mediated polymerase chain reaction to locate the site of viral vector integration by sequencing polymerase chain reaction products. The sequences were compared to genomic databases to characterize respective clones.ResultsThe retroviral vector presented different and non-random profiles of integration between cells lines. A preference of integration for chromosomes 19, 17 and 11 was observed for HepG2FVIIIdB/P140K and chromosome 9 for Hek293FVIIIdB/P140K. In genomic regions such as CpG islands and transcription factor binding sites, there was no difference in the integration profiles for both cell lines. Integration in intronic regions of encoding protein genes (RefSeq genes) was also observed in both cell lines. Twenty percent of integrations occurred at fragile sites in the genome of the HepG2 cell line and 17% in Hek293.ConclusionThe results suggest that the cell type can affect the profile of chromosomal integration of the retroviral vector used; these differences may interfere in the level of expression of recombinant proteins.

Bioengineering coagulation factors for improved hemophilia treatments

“…In conclusion, the study of Fantacini et al represents an additional step of a Brazilian group toward mastering the technology of recombinant coagulation factor concentrate production, 8 which as previously stated, should be regarded as a strategic area of research.…”

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies

“…On the other hand, lentiviral vectors, derived from the retroviral family, Lentiviridae, showed safer and better integration properties than their gamma retroviral counterparts. 25 , 26 Lentiviral vectors are able to insert genetic material into non-dividing cells, 27 whereas gamma retroviral vectors transduce only dividing cells. 28 The advantages of the lentiviral system are reflected in the large number of CAR-T products under development using this system and three of the CAR-T products available on the market use lentiviral vectors (Kymriah, Breyanzi and Abecma).…”

Purificação de fatores de coagulação VIII e VII recombinantes para o tratamento das hemofilias A e B produzidos a partir de células humanas

“…Nosso grupo de pesquisa vem desenvolvendo, há mais de 10 anos, estudos relacionados à produção de fatores coagulação utilizando linhagens de células humanas (PICANCO et al, 2007;PICANCO-CASTRO et al, 2008;RUSSO-CARBOLANTE et al, 2011;SWIECH et al, 2011;DA ROSA et al, 2012;RODRIGUES et al, 2013;CORREA DE FREITAS et al, 2014).…”